Building a platform for long-term growth and impact
2024 annual report
Our purpose is to invest to extend and enhance human life
Watch video
Our team members are experts at what they do
Our people
A diversified portfolio of life science companies
Portfolio

To unlock the potential from truly innovative science to transform patients’ lives

We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses

Who we are

A diversified portfolio across clinical stages

Late-stage clinical companies
Late-stage clinical companies
Clinical companies
Clinical companies
Pre-clinical companies
Pre-clinical companies
Explore our portfolio

Making a positive contribution

We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.

Sustainability

Latest videos

Introducing iOnctura

| Video length 5:52

Expansion of our senior team

| Video length 7:06

Launching Beacon Therapeutics

| Video length 7:36

Scaling for growth

| Video length 09:28

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

| Video length 7:43

Syncona CEO Martin Murphy discusses Clade Series A financing

| Video length 10:16

Anaveon doses first patient

| Video length 6:18

Introduction to Richard Francis, Chief Executive of Purespring Therapeutics

| Video length 3:42

Introduction from Quell Therapeutics, CEO, Iain McGill

| Video length 5:38

Quell: the science and the unmet medical need for patients

| Video length 5:25

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

| Video length 4:25

Introducing Resolution Therapeutics

| Video length 11:28

Introduction to Purespring

| Video length 5:47

Syncona FY20: Martin Murphy discusses FY20 results

| Video length 6:15

Syncona FY20: Martin Murphy discusses the impact of COVID-19

| Video length 4:52

Syncona FY20: Martin Murphy discusses the outlook for Syncona

| Video length 2:53

Achilles doses first patient

| Video length 1:40

Gene Therapy explained

| Video length 3:11
View all videos

Latest insights

Introducing iOnctura

Challenges continue but brighter days on the horizon

Navigating the biotech landscape: A journey from big pharma to innovative startups

Building a platform for the next generation of investors

Expansion of our senior team

Modality precision is the new precision in medicine

Taking a proactive approach to portfolio company sustainability

Launching Beacon Therapeutics

Leveraging the Syncona team for our next phase of growth

Good science must survive in challenging markets

Scaling for growth

Building a global leader in retinal gene therapy

Welcoming our first Windsor Fellowship intern to Syncona

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

Syncona CEO Martin Murphy discusses Clade Series A financing

Alex Hamilton on manufacturing in cell and gene therapy and the role of development partnerships

Ed Hodgkin provides his perspectives from a career in early-stage biotech

Encouraging diversity in the next generation of scientists

View all insights and articles

Latest news

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial

Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies

Spur Therapeutics Presents Promising New Data from its GBA1 Parkinson’s Disease Research Program

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001

Syncona Full Year Results for the 12 months ended 31 March 2024

Spur Therapeutics (Formerly Freeline) Announces New Name and Brand

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Resolution Therapeutics to Host Virtual R&D Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024

Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients

Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

View all news
2024 Annual Report front cover

2024 Annual Report

Our Annual Report and Accounts 2024 provides an overview of our most recent financial year, as we continue to execute our clear strategy for growth and patient impact.

03.07.24 | pdf (4.55Mb)
Download

An expert multi-disciplinary team, attracting world-class talent

We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.

Our people

Investment team key facts

All as of 31 March 2024

12

Members of the investment team

150+

Years of life science and investment expertise

92%

Investment team with PhDs

Search